Drugs in Dev. Immunology
Undisclosed
France 
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Fidia Farmaceutici Spa
Deal Size : Undisclosed
Deal Type : Divestment
Details : The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Fidia Farmaceutici Spa
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inside Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
OSE Immunotherapeutics forms Strategic Collaboration on Novel mRNA Tech
Details : OSE will develop novel RNA therapeutics and delivery methods to fine-tune immune responses in inflammatory disorders and autoimmune diseases, leveraging the advantages of RNA-based therapy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inside Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biosenic Provides Update Regarding Current License Agreement With Phebra
Details : Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Product Name : Arscimed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 29, 2023
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : DBV712
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
Details : DBV712 is a Other Large Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : DBV712
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inolimomab
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Details : Inolimomab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Inolimomab
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MaaT013 is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 24, 2021
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Viaskin Peanut
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viaskin® Peanut (DBV712) Expanded Access Protocol
Details : Viaskin Peanut is a Other Large Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 01, 2020
Lead Product(s) : Viaskin Peanut
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
